Update on the comparative in vitro activity of cefiderocol and four β-lactam-β-lactamase inhibitor combinations against clinically important Gram-negative pathogens
19. September 2024Wohlfarth E., Deuchert F., Gatermann S.G., Higgins P.G., Pfeifer Y., Pfennigwerth N., Seifert H., Werner G. Study Group `Antimicrobial Resistance…In vitro activity of Aztreonam-Avibactam against MBL-producing Enterobacterales isolates across Germany
19. September 2024Wohlfarth E., Deuchert F., Fuchs F., Ziesing S., Becker S.L., Zautner A.E., Higgins P.G., Forster D., Molitor E., Siegel E.,…In vitro activity of ceftazidime-avibactam against ceftazidime- non-susceptible Gram-negative pathogens recovered from hospitalized patients from Germany, Austria and Switzerland, 2019-2020
19. September 2024Wohlfarth E.1*, Kresken M.2, Pfeifer Y.3, Pfennigwerth N.4, Werner G.3, Gatermann S.G.4, Deuchert F.1 Study Group `Antimicrobial Resistance ́ of…Multidrug resistance to oral antibiotics among Escherichia coli urine isolates from patients at outpatient departments in Germany and in vitro activity of nitroxoline, Germany, 2010-2023
19. September 2024Wohlfarth E., Deuchert F, Pfeifer Y, Werner G, Kresken M,Study Group `Antimicrobial Resistance ́ of the Paul-Ehrlich-Society for Infection TherapyAntimicrobial Susceptibility of Bacterial Pathogens from Patientswith Ocular Surface Infections in Germany, 2020–2021: AComparison with the Data from Three Previous National Studies
19. September 2024Esther Wohlfarth, Michael Kresken and Fabian Deuchert